ABSTRACT
The objectives of the study are to develop a cost-effectiveness model comparing biological therapy (BT) with methotrexate (MTX) alone, in the treatment for rheumatoid arthritis (RA), combining clinical and quality-of-life data from international trials with local costs and local epidemiological data. We designed a six-month cycle Markov model with five functional states, based on Health Assessment Questionnaire, with patients initiating treatment in any of the predefined states, based on a sample of 150 local RA patients. Simulations ran for 10 and 20 years, and for the whole life span. Utilities, in quality-adjusted life years (QALY), were taken from international literature. Discount rate was 3 % for costs and utilities. We calculated direct and indirect costs using a combination of international and local data. Results are presented as incremental cost-effectiveness ratios (ICER). ICERs in euros per QALY were
Subject(s)
Antirheumatic Agents/economics , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Biological Therapy/economics , Methotrexate/economics , Methotrexate/therapeutic use , Arthritis, Rheumatoid/economics , Arthritis, Rheumatoid/epidemiology , Colombia/epidemiology , Cost-Benefit Analysis , Female , Humans , Male , Markov Chains , Middle Aged , Quality of Life , Quality-Adjusted Life Years , Surveys and Questionnaires , Time Factors , Treatment OutcomeABSTRACT
Describimos el caso de un paciente de 36 años con artritis reumatoide y miastenia gravis sin respuesta al tratamiento inmunosupresor convencional, quien recibió tratamiento con terapia anti CD-20 (rituximab), con adecuada respuesta clínica de sus dos patologías autoinmunes de base.
The following case presents a 36 year-old patient with rheumatoid arthritis and myasthenia gravis without response with the conventional immunosuppressive treatment, who was managed with anti CD-20 therapy (rituximab), with good clinical evolution of both autoinmune diseases.